Rate My Professor Paul Edison

Professor Edison's research specializations encompass neuroimaging with novel molecular probes using PET and MRI to assess pathophysiological changes in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. His work examines amyloid deposition, microglial activation, tau pathology, glucose metabolism, neuroinflammation, and the interplay between inflammation, immunity, genetics, and cardiometabolic factors. Key findings include the correlation between microglial activation and cognition in Alzheimer's disease, independent of amyloid load. He evaluates therapeutic modulation of inflammation and amyloid, including GLP-1 analogues like liraglutide in the ELAD phase 2b trial. Notable publications include 'Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial' (Nature Medicine, 2025), 'Neuroinflammation in Alzheimer disease' (Nature Reviews Immunology, 2024), 'Astroglial activation: Current concepts and future directions' (Alzheimer's & Dementia, 2024), 'Cardiometabolic risk factors and neurodegeneration' (Journal of Neurology, Neurosurgery & Psychiatry, 2024), and 'Advances in the drug treatment of Alzheimer’s disease: pathophysiology and mechanisms of action' (2026). With 291 publications and over 16,500 citations, his contributions have advanced understanding of neuroinflammation and disease-modifying therapies. He has received several international best paper awards.